ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer

BackgroundThe optimal treatment strategy for women with newly diagnosed ovarian cancer has yet to be determined. Poly(ADP-ribose) polymerase (PARP) inhibitors have demonstrated substantial improvement in progression-free survival as monotherapy maintenance treatment in the frontline setting versus a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of gynecological cancer Jg. 31; H. 12; S. 1589 - 1594
Hauptverfasser:	Monk, Bradley J, Coleman, Robert L, Fujiwara, Keiichi, Wilson, Michelle K, Oza, Amit M, Oaknin, Ana, O’Malley, David M, Lorusso, Domenica, Westin, Shannon N, Safra, Tamar, Herzog, Thomas J, Marmé, Frederik, N Eskander, Ramez, Lin, Kevin K, Shih, Danny, Goble, Sandra, Grechko, Nikolay, Hume, Stephanie, Maloney, Lara, McNeish, Iain A, Kristeleit, Rebecca S
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States BMJ Publishing Group Ltd 01.12.2021 Elsevier Inc by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology BMJ Publishing Group
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - administration & dosage BRCA1 protein BRCA2 protein Carcinoma, Ovarian Epithelial - drug therapy Clinical Trial Double-Blind Method Female homologous recombination Humans Indoles - administration & dosage Maintenance Chemotherapy - methods Nivolumab - administration & dosage ovarian neoplasms Ovarian Neoplasms - drug therapy Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage BRCA2 protein ovarian neoplasms homologous recombination BRCA1 protein
ISSN:	1048-891X, 1525-1438, 1525-1438
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!